{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:21:38Z","timestamp":1790490098456,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40262-020-00916-9","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:36:15Z","timestamp":1596270975000},"page":"103-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-8815","authenticated-orcid":false,"given":"Andrea","family":"Calcagno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Milesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Avataneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Alcantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Pla-Junca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Trunfio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"916_CR1","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.2147\/DDDT.S84850","volume":"9","author":"CE Kandel","year":"2015","unstructured":"Kandel CE, Walmsley SL. Dolutegravir: a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Dev Ther. 2015;9:3547\u201355.","journal-title":"Drug Des Dev Ther"},{"key":"916_CR2","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1517\/14740338.2015.1059818","volume":"14","author":"P Bollen","year":"2015","unstructured":"Bollen P, Reiss P, Schapiro J, et al. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opin Drug Saf. 2015;14:1457\u201372.","journal-title":"Expert Opin Drug Saf"},{"key":"916_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Welz\u00a0T, Sabranskiet M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56\u201363.","journal-title":"HIV Med"},{"key":"916_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QAD.0000000000001351","volume":"31","author":"P Bonfanti","year":"2017","unstructured":"Bonfanti P, Madeddu G, Gulminetti R,\u00a0et al. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS Lond Engl. 2017;31:455\u20137.","journal-title":"AIDS Lond Engl"},{"key":"916_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/QAI.0000000000002250","volume":"83","author":"L Greenberg","year":"1999","unstructured":"Greenberg L, Ryom\u00a0L, Wandeleret G, et al. Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting. J Acquir Immune Defic Syndr. 1999;83:240\u201350.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"916_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/1574886313666180116124046","volume":"13","author":"F Parant","year":"2018","unstructured":"Parant F, Miailhes P, Brunel F, et al. Dolutegravir-related neurological adverse events: a case report of successful management with therapeutic drug monitoring. Curr Drug Saf. 2018;13:69\u201371. https:\/\/doi.org\/10.2174\/1574886313666180116124046.","journal-title":"Curr Drug Saf"},{"key":"916_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12879-017-2717-x","volume":"17","author":"H Yagura","year":"2017","unstructured":"Yagura H, Watanabe\u00a0D, Kushidaet H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17:622.","journal-title":"BMC Infect Dis"},{"key":"916_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/jac\/dky508","volume":"74","author":"A Borghetti","year":"2019","unstructured":"Borghetti A, Calcagno A, Lombardi F et al. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019;74:1035\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"916_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s15010-015-0795-5","volume":"43","author":"A Calcagno","year":"2015","unstructured":"Calcagno A, Nozza S, Mussi C et al. Ageing with HIV: a multidisciplinary review. Infection. 2015;43:509\u201322.","journal-title":"Infection"},{"key":"916_CR10","first-page":"1354","volume":"68","author":"A Winston","year":"2013","unstructured":"Winston A, \u00a0Jose S, Gibbons S,\u00a0et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68:1354\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"916_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/QAD.0000000000002372","volume":"34","author":"P Courle","year":"2020","unstructured":"Courle P, \u00a0Stader\u00a0F, Guidiet M, et al. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. AIDS. 2020;34:103\u20138.","journal-title":"AIDS"},{"key":"916_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpba.2017.02.002","volume":"138","author":"M Simiele","year":"2017","unstructured":"Simiele M, \u00a0Ariaudo\u00a0A, De Nicol\u00f2\u00a0A\u00a0et al. UPLC-MS\/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. J Pharm Biomed Anal. 2017;138:223\u201330.","journal-title":"J Pharm Biomed Anal"},{"key":"916_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/FTD.0000000000000290","volume":"38","author":"V Cozzi","year":"2016","unstructured":"Cozzi V, Charbe N, Baldelli S\u00a0et al. Development and validation of a chromatographic ultraviolet method for the simultaneous quantification of dolutegravir and rilpivirine in human plasma. Ther Drug Monit. 2016;38:407\u201313.","journal-title":"Ther Drug Monit"},{"key":"916_CR14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bcp.12639","volume":"80","author":"J Zhang","year":"2015","unstructured":"Zhang J, \u00a0Hayes\u00a0S, Sadler\u00a0BM et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80:502\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"916_CR15","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/jac\/dkz217","volume":"74","author":"C Barcelo","year":"2019","unstructured":"Barcelo C, Aouri\u00a0M, Courletet P, et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother. 2019;74:2690\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"916_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciy426","volume":"68","author":"ER Elliot","year":"2019","unstructured":"Elliot ER, \u00a0Wang\u00a0X, Singh S\u00a0et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68:87\u201395.","journal-title":"Clin Infect Dis"},{"key":"916_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/jac\/dkx461","volume":"73","author":"A Palazzo","year":"2018","unstructured":"Palazzo A, Trunfio M, Pirriatore V et al. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. J Antimicrob Chemother. 2018;73:826\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"916_CR18","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1111\/hiv.12540","volume":"19","author":"AF Capetti","year":"2018","unstructured":"Capetti AF, Di Giambenedetto S, Latini A\u00a0et al. Morning dosing for dolutegravir-related insomnia and sleep disorders. HIV Med. 2018;19:e62\u2013e6363.","journal-title":"HIV Med"},{"key":"916_CR19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/sj.jcbfm.9600462","volume":"27","author":"S Stoquart-ElSankari","year":"2007","unstructured":"Stoquart-ElSankari S, Bal\u00e9dent O, Gondry-Jouet C\u00a0et al. Aging effects on cerebral blood and cerebrospinal fluid flows. J Cereb Blood Flow Metab. 2007;27:1563\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"key":"916_CR20","doi-asserted-by":"publisher","first-page":"ofz74","DOI":"10.1093\/ofid\/ofz174","volume":"6","author":"T Gel\u00e9","year":"2019","unstructured":"Gel\u00e9 T, Furlan\u00a0V, Taburetet AM et al. Dolutegravir cerebrospinal fluid diffusion in HIV-1-infected patients with central nervous system impairment. Open Forum Infect Dis. 2019;6:ofz74.","journal-title":"Open Forum Infect Dis."},{"key":"916_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/QAD.0000000000002063","volume":"33","author":"D De Francesco","year":"2019","unstructured":"De Francesco D, Wit\u00a0FW, B\u00fcrkle\u00a0A\u00a0et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? AIDS. 2019;33:259\u201368.","journal-title":"AIDS"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00916-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00916-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00916-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T23:17:07Z","timestamp":1627773427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00916-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00916-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,1]]},"assertion":[{"value":"1 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was carried out as part of our routine work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Andrea Calcagno has received honoraria from Gilead, Insmed, Janssen-Cilag, MSD and Viiv and he is currently receiving research grants from Gilead and Viiv. Giovanni Di Perri and Stefano Bonora have received honoraria from Abbvie, BMS, Gilead, Janssen-Cilag, MSD and Viiv. Jos\u00e9 Molt\u00f3, Borghetti Alberto, Gervasoni Cristina, Maurizio Milesi, Marta Valle, Valeria Avataneo, Chiara Alcantarini, Francesc Pla-Junca, Trunfio Mattia, Antonio D\u2019Avolio, Simona Di Giambenedetto and Dario Cattaneo have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}